This specialist declared the following: “This is a very interesting diet pill that works in a different way that what we knew untill now. It’s very promising and more than that,because we allready have proves that shows that to us.” Dr. Pi-Sunyear’s reserche found that patiens who were treated with Rimonabant lost weight more then any other diet pills and were able to keep it off for two years. The first in a new class of drugs known as CB-1 receptors, Rimonabant is an appetite suppressant that stops chemical messages of hunger from getting through to the brain. The result is not only weight loss but also better regulation of sugar and fat metabolism.

Another benefit outcome of clinical trials of Acomplia is that the drug also appears to reduce cravings for nicotine. According to a trial study reported by the North American Association for the Study of Obesity (NAASO), smokers who took Rimonabant were twice as likely to quit. Further, there was no weight gain associated with quitting, which is often a concern for smokers, especially if they are already overweight. So,the conclusion is that Rimonabant can be used also as a pill for helping people quit smoking.

In another study, this one a joint effort of NAASO and the American Diabetes Association, 38% of the patiens in a group randomized to receive 20 mg of Rimonabant daily stopped smoking after 10 weeks. The subjects who stopped smoking gained an average of only 0,5 pounds. This was in contrast to the fact that only 16% of subjects in a placebo group stopped smoking after 10 weeks. Those in the placebo group who did stop smoking gained an average of 6 pounds. Althought Rimonabant has not officially been approved for use as a smoking cessation aid, its effects on smoking are quite encouraging.

Besides this two big benefits  Acomplia helps people with other problems and diseases such as diabeatis,cardiovascular risks and the newest one is resistens to alcohol fat building effect in the liver.

Alcoholic fatty liver is a cause for  more serious disease, and alcoholism is a leading cause of liver disease in the U.S. and other countries.

“Clinical trials testing the effectiveness of CB1 receptor blockers in the treatment of both alcoholic and nonalcoholic fatty liver and their more severe sequelae may be warranted,” the researchers concluded.

The researchers recruited more than 1,500 obese adults from 60 European and U.S. centers. Inclusion criteria were a body mass index (BMI) of 30 or a BMI of 27 plus hypertension or dyslipidemia. Participants also were required to have experienced less than 11-lb (5-kg) variation in body weight in the three months before the study, and to be free from significant cardiovascular, pulmonary, hepatic, renal, neurologic, psychiatric, and endocrine disease, including diabetes. Participants were excluded if they had a history of surgical procedures for weight loss or of significant depression, were currently taking medications known to influence body weight, or intended to change their smoking status during the study period.

After extensive baseline assessment, including basal metabolic rate, body measurements, glucose tolerance testing, and other laboratory screening, 1,507 participants were randomly assigned to 5 mg per day of rimonabant, 20 mg per day of rimonabant, or placebo. All patients were advised on diet and exercise based on their personal basal metabolic rate. Patients were reassessed every 14 days for one month, then every 28 days for two years.

Patients in the three groups were comparable in all significant variables at baseline. Only 61 percent of participants completed the one-year follow-up: 379 (62.7 percent) in the 5-mg group, 363 (60.6 percent) in the 20-mg group, and 178 (58.4 percent) in the placebo group. Using intention-to-treat analysis, researchers found that patients taking rimonabant had significantly greater weight loss and improvement in lipids and insulin function after one year than those taking placebo. This effect was more pronounced if the analysis was limited to participants who completed one year of assigned therapy. In this analysis, the cumulative weight loss was 11 lb (5 kg) in the placebo group, compared with more than 22 lb (10 kg) in the 20-mg group. The percentage of patients with 10 percent or more weight loss was significantly greater in the 20-mg group (27.4 percent) than the placebo group (7.3 percent) but not in the 5-mg group (10.1 percent). If only those patients who completed the study were considered, these figures rose to 39 percent in the 20-mg group, 12.4 percent in the placebo group, and 15.3 percent in the 5-mg group. Waist circumference and lipid profile also improved significantly in patients taking rimonabant. The proportion of patients with metabolic syndrome decreased from 41.2 to 28.6 percent in those taking 5 mg and from 42.2 to 19.6 percent in those taking 20 mg, compared with a decrease from 39.9 to 31.4 percent in the placebo group. In about one half of participants, improvement in metabolic risk factors was independent of weight loss. Adverse effects were reported by more than 80 percent of patients in all three groups but most were mild and transitory. The greatest number of discontinuations (87) occurred in the 20-mg group, with almost one half (42) being attributed to psychiatric disturbance.

In late June, Sanofi-Aventis withdrew its application to gain U.S. approval for rimonabant study, following a meeting in which government advisers rejected the treatment on safety grounds. The Paris-based company said it would resubmit its Food and Drug Administration application for rimonabant study at a later date.Despite the rimonabant issues, HSBC analyst Kevin Scotcher on Wednesday raised his rating on Sanofi shares to “Overweight” or “Buy” from “Neutral,” citing the company’s new drug portfolio.”Given the share price decline post the failure to commercialise rimonabant in the U.S. in 2007, we nonetheless point out that Sanofi has numerically the fullest pipeline among the 11 U.S. and European drug majors under our coverage,” Scotcher wrote in a note to investors.HSBC did lower its price target on the shares to 71 euros ($98) from 72.50 euros, however. The analyst pointed to risks including the possibility that Sanofi could launch a highly leveraged takeover of American rival Bristol-Myers Squibb Co.The uncertain future for rimonabant weight loss raises pressure on the French drug maker to make acquisitions to boost its drug portfolio, analysts have said.Scotcher said generic versions of Plavix, which is Bristol-Myers Squibb Co.’s best selling product, could enter the market before patent expiration. Sanofi-Aventis sells Plavix in the United States through Bristol-Myers.Shares of Sanofi-Aventis fell 26 cents to $42.45 in afternoon trading on below-average volume. Shares of Bristol-Myers fell 31 cents to $31.84 in afternoon trading, but earlier in the day hit a 52-week high of $32.35.

Anti-obesity drugs are the prime requirement of millions of obese across the world. Only an obese knows well about the problem related with obesity. Every third person tries to instruct an obese what to eat and what not to. There are people who laugh at an obese. Every obese knows that obesity can be cured with the help of suppression of appetite and proper exercising. Both things are easy to suggest but difficult to do. Exercising needs time and where is the time in the busy schedule to do rigorous exercising? How can an obese suppress appetite when urge for food is acute?

Appetite can be effectively suppressed with the aid of appetite suppressing drugs(rimonabant weight loss). The list of such drugs is long but most of them are in the weight loss drug market for years and obesity is still there. This puts a big question mark on the efficacy of those appetite suppressants. Recently, Sanofi-Aventis a drug manufacturing company of France has launched a new medication in the European anti-obesity drug market.This drug is introduced by name of rimonabant weight loss and was initially launched in the UK drug market where countless obese found it very effective. rimonabant weight loss is a product of advance drug development technology whose line action of is quiet different from almost all anti-obesity medication available in the market. Cells of our body have neurotic receptors named as cannaboid receptor-1; this receptor is responsible for the transmission of hunger signal to the brain. The substance, which can block the working of CB-1 receptor, can be a proven appetite suppressant. 2006 rimonabant’s active ingredient Rimonabant 2006 does this work. rimonabant can also help in the cessation of smoking by inhibiting the working of the CB-1 receptor. Tags:rimonabant 2006,[rimonabant study],(rimonabant weight loss)